Small-Cap Healthcare Stock Comparison
New MarketBeat Analysis Compares Valuation and Risk Across Five Small-Cap Healthcare Stocks
Anonymous
Key Points
1
Evaxion A/S has a beta of 0.26, meaning its shares have been 74% less volatile than the S&P 500, while Nektar Therapeutics has a beta of 1.14, or 14% more volatility than the index.
2
Iovance Biotherapeutics’ shares are held 77.0% by institutional investors, compared with 72.4% insider ownership at eXoZymes; Iovance’s institutional backing was cited as an indicator of potential long-term investor confidence.
3
Trinity Biotech had substantially higher institutional ownership than Varex Imaging, with institutions holding 79.0% of Trinity’s shares versus 4.6% insider ownership at Varex; Trinity’s stock also had the lower beta, at 0.74 versus Varex’s 0.96.
4
Mereo BioPharma Group’s consensus target price was $1.67, implying 495.24% potential upside, while Veracyte’s $55.78 target implied 36.48% upside; Mereo also had a much lower beta of 0.32 versus Veracyte’s 1.93.
5
Black Diamond Therapeutics had 95.5% institutional ownership compared with 11.0% for Evaxion A/S, but its beta of 3.31 indicated substantially higher volatility than Evaxion’s 0.26; insider ownership was 9.3% at Black Diamond and 41.6% at Evaxion.
Five head-to-head comparisons of small-cap healthcare stocks reveal wide gaps in valuation, risk, and investor backing. MarketBeat-based analysis shows that some stocks trade at cheaper prices while others offer higher growth potential, with volatility ranging from stable blue-chip characteristics to highly unpredictable swings. These matchups help investors identify which companies appear stronger across 13 to 15 different financial and market measures.
Nektar Beats Evaxion on Value, Despite Lower Upside
Nektar Therapeutics outperformed Evaxion A/S on nine of 15 measures, earning the title of more affordable stock. Yet Evaxion shows the steadier ride: its beta of 0.26 means shares swing 74% less than the S&P 500, while Nektar's 1.14 beta adds 14% more volatility. MarketBeat noted Evaxion's consensus target implied larger projected upside, but Nektar won on fundamentals like profitability and institutional confidence.
Iovance Leads eXoZymes With Stronger Institutional Support
Iovance Biotherapeutics dominated eXoZymes on eight of 14 factors, backed by 77.0% institutional ownership versus eXoZymes' 72.4% insider control. Iovance also posted lower volatility and a more favorable analyst outlook. MarketBeat flagged Iovance's heavy institutional backing as a sign of long-term investor confidence in the company's direction and strategy.
Varex Wins on Metrics, But Trinity Holds More Insider Trust
Varex Imaging bested Trinity Biotech on 10 of 13 measures, yet the comparison tells a nuanced story. Trinity captured 79.0% institutional ownership against Varex's modest 4.6%, and Trinity's beta of 0.74 beat Varex's 0.96, signaling calmer trading. Varex's consensus analyst target, however, implied downside rather than upside potential according to MarketBeat's assessment.
Veracyte Outpaces Mereo Except on Upside and Stability
Veracyte outshined Mereo BioPharma Group on 11 of 15 factors, powered by higher revenue and stronger earnings. Mereo, however, flipped the script on two key counts: its consensus target price of $1.67 implied 495.24% potential upside, far exceeding Veracyte's 36.48% forecast. Mereo also boasted rock-solid stability with a beta of just 0.32 versus Veracyte's volatile 1.93 beta.
Black Diamond Crushes Evaxion Despite Wild Price Swings
Black Diamond Therapeutics beat Evaxion on nine of 13 factors, showing higher revenue, stronger earnings, and tighter valuation. Institutional ownership favored Black Diamond at 95.5% versus Evaxion's 11.0%. The downside: Black Diamond's beta of 3.31 indicated substantially higher volatility than Evaxion's calm 0.26. MarketBeat highlighted the tradeoff between Black Diamond's stronger fundamentals and its risky price swings.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
12
Reach
31
A
AnonymousAuthor
